Skip to main content
MJFF Feed

Clinical Results for Novel Parkinson’s Drugs Targeting Adenosine Continue to Come In

Clinical Results for Novel Parkinson’s Drugs Targeting Adenosine Continue to Come In

Yesterday, we reported positive clinical study results into a symptomatic treatment for Parkinson’s disease from Biotie Therapies, which targets a brain chemical called adenosine.  And today, a quick addendum, as more positive trial results focused on adenosine were announced from another company – the British-based Vernalis. 

According to Vernalis, the study confirmed the appropriate dose of their drug, called V8144, to be used in a forthcoming phase 2 trial, which is scheduled to begin in the first half of 2013.  

Merck also has a Parkinson's drug targeting adenosine in the third phase of clinical testing.

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.